The Scientist

» clinical trials and immunology

Most Recent

image: TS Picks: December 30, 2015

TS Picks: December 30, 2015

By | December 30, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Pregnancy May Explain Ebola Return

Pregnancy May Explain Ebola Return

By | December 21, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: When the Flu Vax Fails

When the Flu Vax Fails

By | December 16, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Ebola’s Effects on the Eye

Ebola’s Effects on the Eye

By | November 30, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Stem Cell Biologist Dies

Stem Cell Biologist Dies

By | November 23, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Birth of the Skin Microbiome

Birth of the Skin Microbiome

By | November 17, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Clinical Trial Data Underreported: Study

Clinical Trial Data Underreported: Study

By | November 16, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

0 Comments

image: Oncologist Found Guilty of Misconduct

Oncologist Found Guilty of Misconduct

By | November 9, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

3 Comments

Overvaluing startups; undervaluing human research participants; curing aging?

1 Comment

image: Microbes Play Role in Anti-Tumor Response

Microbes Play Role in Anti-Tumor Response

By | November 5, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

1 Comment

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech